A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells

Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells

(2016) Jen-Chung Ko et al.   BIOCHEMICAL PHARMACOLOGY

Insulin-like growth factor-1 receptor regulates repair of ultraviolet B-induced DNA damage in human keratinocytes in vivo

(2016) Mathew M. Loesch et al.   Molecular Oncology

CHK1 as a therapeutic target to bypass chemoresistance in AML

(2016) Laure David et al.   Science Signaling

CHK1 as a therapeutic target to bypass chemoresistance in AML

(2016) Laure David et al.   Science Signaling

DNA damage control: regulation and functions of checkpoint kinase 1

(2015) Veronique A. J. Smits et al.   FEBS Journal

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation

(2015) K. Mikami et al.   MOLECULAR CANCER RESEARCH

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer

(2015) Nouf Alsubhi et al.   Molecular Oncology

MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors

(2014) Paolo Luraghi et al.   CANCER RESEARCH

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells

(2014) Na Song et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

(2014) Tarek M.A. Abdel-Fatah et al.   Molecular Oncology

A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation

(2014) Y Yan et al.   ONCOGENE

Roles of Chk1 in cell biology and cancer therapy

(2013) Youwei Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

(2013) Yohei Funakoshi et al.   INVESTIGATIONAL NEW DRUGS

Akt Switches TopBP1 Function from Checkpoint Activation to Transcriptional Regulation through Phosphoserine Binding-Mediated Oligomerization

(2013) K. Liu et al.   MOLECULAR AND CELLULAR BIOLOGY

Inhibition of the PI3K/Akt/GSK3 Pathway Downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD Downregulates DNA Damage-Induced Chk1 Activation as Well as G2/M Arrest and Prominently Enhances Induction of Apoptosis

(2013) Tetsuya Kurosu et al.   PLoS One

Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

(2013) L Chang et al.   Cell Death & Disease

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

(2012) Remko Prevo et al.   CANCER BIOLOGY & THERAPY

Chk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signalling

(2012) Ning Liu et al.   EMBO JOURNAL

PTEN Positively Regulates UVB-Induced DNA Damage Repair

(2011) M. Ming et al.   CANCER RESEARCH

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Expression of DNA Damage Checkpoint Proteins and Prognostic Implication in Metastatic Brain Tumors

(2011) Ho Jun Seol et al.   ONCOLOGY RESEARCH

Akt Activation Emulates Chk1 Inhibition and Bcl2 Overexpression and Abrogates G2 Cell Cycle Checkpoint by Inhibiting BRCA1 Foci

(2010) Ivana Tonic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2

(2010) Naihan Xu et al.   JOURNAL OF CELL BIOLOGY